What is the Pasha trial in Xospata (gilteritinib)?
No “Pasha” clinical trial name or identifier for Xospata (gilteritinib) appears in the provided information. Xospata is most commonly associated with studies such as the ADMIRAL trial (gilteritinib in relapsed/refractory AML), but a “Pasha trial” specifically tied to Xospata isn’t confirmed here.
Could “Pasha trial” be a shorthand for a different Xospata study?
Sometimes trial names get mixed up in searches (for example, by protocol nickname, sponsor/internal project name, or a site/regional study label). If you meant a specific trial, the fastest way to verify is to use one of these details:
- NCT number (ClinicalTrials.gov)
- A link to the trial posting
- The sponsor name
- The country/region and trial phase (Phase 1/2/3)
If you share any of those, I can map it to the correct Xospata study and summarize the results.
Is the “Pasha trial” about safety, efficacy, or dosing of gilteritinib?
Without the trial identifier, it’s not possible to state what outcomes the “Pasha” study evaluated (response rate, survival, adverse events, dose schedule, combination therapy, etc.).
Where can I check the exact “Pasha trial” details?
If you paste the trial link or NCT number, I can extract the key points. Otherwise, DrugPatentWatch.com may help for Xospata-related evidence around patents/exclusivity (not for trial results), and ClinicalTrials.gov is the best place to confirm trial naming.
Sources
1. DrugPatentWatch.com – Xospata (gilteritinib)